Scientific Publications
June 30, 2023
Hawaii Global Summit for Thoracic Malignancies
Neoantigen-targeting TCR engineered cellular therapy for TP53, EGFR and RAS-mutant tumors
SUBJECT: TCR
June 3, 2023
American Society of Clinical Oncology (ASCO) 2023
Safety and Efficacy of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations Expressed by Solid Tumors in First-in-Human Phase 1 Study
SUBJECT: TCR
November 10, 2022
Society for Immunotherapy of Cancer (SITC) 2022
SUBJECT: TCR
September 30, 2022
CRI-ENCI-AACR (CICON22) Presentation by Dr. Marcelo Negrao
First two patients treated in TCR-T Library Phase 1/2 Trial had manageable safety profiles with no dose limiting toxicities; Patient 1 achieved a confirmed partial response, Patient 2’s achieved best overall response of stable disease
SUBJECT: TCR
September 21, 2022
Abstract: CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
First patient treated in TCR-T Library Phase ½ Trial achieved a confirmed partial response and Sleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observed
SUBJECT: TCR
September 12, 2022
European Society of Medical Oncology (ESMO) 2022
Commencement of First-in-human Phase 1/2 TCR-T Clinical Trial Targeting Shared Tumor-specific Hotspot Mutations in Solid Tumors
SUBJECT: TCR
June 5, 2022
American Society of Clinical Oncology (ASCO) 2022
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors
SUBJECT: TCR
May 16, 2022
American Society for Gene and Cell Therapy (ASGCT) 2022
Stem-cell memory TCR-T cells targeting hotspot EGFR, KRAS and p53 neoantigens generated through co-expression of membrane-bound Interleukin-15
SUBJECT: TCR
November 13, 2021
Society for Immunotherapy of Cancer (SITC) 2021
Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers.
SUBJECT: TCR
June 9, 2021
Drew Deniger, Vice President of Immunology, presentation at the Federation of American Societies for Experimental Biology (FASEB) virtual conference held on Wednesday June 9, 2021, entitled “Development of Sleeping Beauty Transposed TCR-T Cells for Adoptive Cell Therapy of Cancer”
SUBJECT: TCR
April 12, 2021
2021 Annual Meeting for American Association for Cancer Research (AACR)
SUBJECT: TCR
December 8, 2019
61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando
Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-generated NY-ESO-1-specific TCR-T Cells Co-expressing Membrane-bound IL-15 Yields Antitumor Responses
SUBJECT: TCR
June 16, 2016
The American Society of Gene & Cell Therapy
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
SUBJECT: TCR
Back to TOP